{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:45:48Z","timestamp":1791917148948,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pmed.1005274","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000}}],"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD083292"],"award-info":[{"award-number":["R01HD083292"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spontaneous early preterm birth (EPB\u2009&lt;\u200934 weeks) is a major contributor to newborn morbidity and mortality; it depends on ancestry, and preventive measures are limited. The insertion (I) allele of the fatty acid desaturase (FADS) Indel polymorphism (rs66698963) modulates FADS1 expression, and increases arachidonic acid synthesis, enhancing parturifacient prostaglandins. Omega-3 docosahexaenoic acid (DHA) inhibits this pathway. Whether FADS Indel genotype predicts response to DHA dose in pregnancy is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>To determine whether FADS Indel genotype modifies the effect of DHA dose on gestational length, we conducted a post hoc secondary analysis of the Assessment of DHA on Reducing Early Preterm Birth (ADORE) trial (NCT02626299). The FADS Indel, the only genetic variant measured, was selected on mechanistic grounds and genotyped blind to outcome. The analysis included all participants consenting to genetic analysis (12\u201320 weeks gestation) at three US medical centers. Participants received 200 or 1,000 mg\/d DHA and were genotyped for FADS Indel (D\/D, I\/D, I\/I). Primary outcomes were EPB and preterm birth (PB,\u2009&lt;37 weeks) analyzed using treatment-specific Bayesian binomial models. Cervical length was assessed in 574 participants.<\/jats:p>\n                    <jats:p>\n                      Women (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910,497) were screened for eligibility from June 8th 2016, to March 13th 2020, 1,032 (1,000 mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009540; 200 mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009492) completed the ADORE trial. A total of 761 (1,000 mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009396; 200 mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009365) are included in this secondary analysis. Participants carrying at least one FADS Indel I allele (I\/I\u2009+\u2009I\/D) receiving low-dose DHA had 4.3% EPB (9\/214; 95% Credible Interval (CrI) [2.0%, 7.3%]) versus 0.8% in the D\/D group (1\/151; 95% CrI [0.04%, 2.7%]; Posterior Probability (PP) = 0.99), and 14.5% PB (31\/214; 95% CrI [10.1%, 19.5%]) versus 8.7% in the D\/D group (13\/151; 95% CrI [4.7%, 13.6%]; PP\u2009=\u20090.96). High-dose DHA was associated with reduced EPB in the I-allele group (1.1%; 2\/205; 95% CrI [0.2%, 2.8%]; PP\u2009=\u20090.99), and PB (9.3%; 19\/205; 95% CrI [5.7%, 13.6%]; PP\u2009=\u20090.95), with little effect in the D\/D group. Birth at \u226540 weeks was more frequent in the high-dose D\/D group. Black women had higher rates of PB and EPB, have higher rates of the I allele, and benefited most from 1,000 mg\/d dose. These dose effects credibly differ by genotype for EPB and prolonged gestation (genotype\u2009\u00d7\u2009dose interaction PP\u2009=\u20090.99 and 0.98). Both genotypes reduced PB similarly with high-dose DHA (PP\u2009=\u20090.56). Although genetic analysis was anticipated and genotyping was completed blind to outcome, this was a post hoc analysis and the genotype-by-dose comparison was not a prespecified trial aim. Some subgroups contained few PB and EPB events, so these estimates, particularly for PB, should be interpreted cautiously and confirmed prospectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The FADS Indel is a functional, mechanistically grounded polymorphism whose frequency varies with race\/ethnicity. Preterm and early preterm birth were lower in the I-allele group receiving high-dose DHA (1,000 mg\/d), while prolonged gestation was more frequent in the D\/D group receiving high-dose DHA. FADS Indel genotypes predicted the direction of the response to high-dose DHA for EPB and prolonged gestation, whereas its modest PB benefit was shared by both genotypes. Analysis by retrospectively pairing high dose to I-carrier genotype and low dose to D\/D was associated with the highest proportion of births at 37\u201340 weeks. These findings identify the FADS Indel as a potential predictive biomarker for DHA dose response and support a genotype-informed, precision-medicine strategy to optimize gestational length by reducing preterm birth in the I-allele group and prolonged gestation in the D\/D group across racially\/ethnically diverse populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinical trial identification number: NCT02626299, Date of registration: December 8, 2015, Date of Initial participant enrolled: June 8, 2016\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02626299\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/study\/NCT02626299<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1005274","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:47:16Z","timestamp":1791481636000},"page":"e1005274","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2119-2250","authenticated-orcid":true,"given":"Yan Ning","family":"Li","sequence":"first","affiliation":[{"name":"Dell Pediatric Research Institute","place":["Austin, Texas, United States of America"],"department":["Dell Medical School and Department of Nutritional Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-1023","authenticated-orcid":true,"given":"Kumar S. D.","family":"Kothapalli","sequence":"additional","affiliation":[{"name":"Dell Pediatric Research Institute","place":["Austin, Texas, United States of America"],"department":["Dell Medical School and Department of Nutritional Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Carlson","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center","place":["Kansas City, Kansas, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7589-8247","authenticated-orcid":true,"given":"Byron J.","family":"Gajewski","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center","place":["Kansas City, Kansas, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-5703","authenticated-orcid":true,"given":"Emily A.","family":"DeFranco","sequence":"additional","affiliation":[{"name":"University of Kentucky","place":["Lexington, Kentucky, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-4245","authenticated-orcid":true,"given":"J. Thomas","family":"Brenna","sequence":"additional","affiliation":[{"name":"Dell Pediatric Research Institute","place":["Austin, Texas, United States of America"],"department":["Dell Medical School and Department of Nutritional Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"2","key":"pmed.1005274.ref001","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2352-4642(21)00311-4","article-title":"Global, regional, and national causes of under-5 mortality in 2000-19: An updated systematic analysis with implications for the Sustainable Development Goals","volume":"6","author":"J Perin","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"7","key":"pmed.1005274.ref002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41372-020-0635-z","article-title":"Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008-2016","volume":"40","author":"AL Beam","year":"2020","journal-title":"J Perinatol"},{"key":"pmed.1005274.ref003","author":"JA Martin","year":"2019"},{"key":"pmed.1005274.ref004","author":"CDC"},{"key":"pmed.1005274.ref005","doi-asserted-by":"crossref","first-page":"1275776","DOI":"10.3389\/fpubh.2023.1275776","article-title":"Health disparities in preterm births","volume":"11","author":"J Brown","year":"2023","journal-title":"Front Public Health"},{"issue":"8","key":"pmed.1005274.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287919","article-title":"Correlates of low birth weight and preterm birth in India","volume":"18","author":"A Jana","year":"2023","journal-title":"PLoS One"},{"issue":"8","key":"pmed.1005274.ref007","doi-asserted-by":"crossref","first-page":"101024","DOI":"10.1016\/j.ajogmf.2023.101024","article-title":"Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: A systematic review and meta-analysis","volume":"5","author":"A-M Aubin","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"pmed.1005274.ref008","article-title":"SMFM Consult Series #70: Management of short cervix in individuals without a history of spontaneous preterm birth","volume":"231","author":"Society for Maternal-Fetal Medicine (SMFM)","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"pmed.1005274.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002390","article-title":"Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial","volume":"14","author":"CA Crowther","year":"2017","journal-title":"PLoS Med"},{"issue":"10033","key":"pmed.1005274.ref010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(16)00350-0","article-title":"Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): A multicentre, randomised, double-blind trial","volume":"387","author":"JE Norman","year":"2016","journal-title":"Lancet"},{"key":"pmed.1005274.ref011","first-page":"1115","article-title":"ACOG Committee Opinion. Use of progesterone to reduce preterm birth","volume":"102","author":"American College of Obstetricians and Gynecologists","year":"2003","journal-title":"Obstet Gynecol"},{"key":"pmed.1005274.ref012"},{"issue":"11","key":"pmed.1005274.ref013","article-title":"Omega-3 fatty acid addition during pregnancy","volume":"11","author":"P Middleton","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pmed.1005274.ref014","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/aogs.14527","article-title":"Birthweight and gestational age in the Faroe Islands: A comparison between birthweight and gestational age in the Faroe Islands and other Nordic countries","volume":"102","author":"SH Olsen","year":"2023","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"pmed.1005274.ref015","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1095\/biolreprod60.3.698","article-title":"Delay of preterm delivery in sheep by omega-3 long-chain polyunsaturates","volume":"60","author":"M Baguma-Nibasheka","year":"1999","journal-title":"Biol Reprod"},{"issue":"2","key":"pmed.1005274.ref016","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00404-017-4418-5","article-title":"The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach","volume":"296","author":"R Bakker","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"pmed.1005274.ref017","doi-asserted-by":"crossref","first-page":"101165","DOI":"10.1016\/j.plipres.2022.101165","article-title":"Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions","volume":"86","author":"SC Dyall","year":"2022","journal-title":"Prog Lipid Res"},{"issue":"2","key":"pmed.1005274.ref018","doi-asserted-by":"crossref","first-page":"101251","DOI":"10.1016\/j.ajogmf.2023.101251","article-title":"Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth","volume":"6","author":"I Cetin","year":"2024","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"7","key":"pmed.1005274.ref019","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/molbev\/msw049","article-title":"Positive selection on a regulatory insertion-deletion polymorphism in FADS2 influences apparent endogenous synthesis of arachidonic acid","volume":"33","author":"KSD Kothapalli","year":"2016","journal-title":"Mol Biol Evol"},{"issue":"2","key":"pmed.1005274.ref020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ajcnut.2024.06.004","article-title":"Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: A secondary analysis of the seAFOod polyp prevention trial","volume":"120","author":"G Sun","year":"2024","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"pmed.1005274.ref021","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/ajcn\/nqy063","article-title":"A regulatory insertion-deletion polymorphism in the FADS gene cluster influences PUFA and lipid profiles among Chinese adults: A population-based study","volume":"107","author":"P Li","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"pmed.1005274.ref022","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.eclinm.2021.100905","article-title":"Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial","volume":"36","author":"SE Carlson","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"10","key":"pmed.1005274.ref023","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"RG Amado","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"pmed.1005274.ref024","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"CS Karapetis","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1005274.ref025","doi-asserted-by":"crossref","first-page":"101358","DOI":"10.1016\/j.ajogmf.2024.101358","article-title":"Racial disparity in efficacy of docosahexaenoic acid supplementation for prevention of preterm birth: Secondary analysis from a randomized, double-blind trial","volume":"6","author":"EA DeFranco","year":"2024","journal-title":"Am J Obstet Gynecol MFM"},{"key":"pmed.1005274.ref026","article-title":"Shifts in the distribution of births by gestational age: United States, 2014-2022","volume":"73","author":"JA Martin","year":"2024","journal-title":"National Vital Statistics Reports"},{"issue":"1","key":"pmed.1005274.ref027","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12884-017-1244-5","article-title":"Assessment of DHA on reducing early preterm birth: The ADORE randomized controlled trial protocol","volume":"17","author":"SE Carlson","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"pmed.1005274.ref028","doi-asserted-by":"crossref","DOI":"10.1201\/EBK1439825488","volume-title":"Bayesian Adaptive Methods for Clinical Trials","author":"SM Berry","year":"2010"},{"issue":"8","key":"pmed.1005274.ref029","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1471-0528.16168","article-title":"Omega-3 fatty acid supplementation in pregnancy-baseline omega-3 status and early preterm birth: Exploratory analysis of a randomised controlled trial","volume":"127","author":"LA Simmonds","year":"2020","journal-title":"BJOG"},{"key":"pmed.1005274.ref030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.placenta.2020.12.012","article-title":"PGE2 vs PGF2\u03b1 in human parturition","volume":"104","author":"W-J Li","year":"2021","journal-title":"Placenta"},{"issue":"10","key":"pmed.1005274.ref031","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/archdischild-2018-316486","article-title":"Racial disparities in preterm birth in USA: A biosensor of physical and social environmental exposures","volume":"104","author":"HH Burris","year":"2019","journal-title":"Arch Dis Child"},{"issue":"2","key":"pmed.1005274.ref032","first-page":"60","article-title":"New understandings of the pathway of long-chain polyunsaturated fatty acid biosynthesis","volume":"25","author":"JT Brenna","year":"2022","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"6","key":"pmed.1005274.ref033","first-page":"1866","article-title":"Triangulation in aetiological epidemiology","volume":"45","author":"DA Lawlor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"pmed.1005274.ref034","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-food-032519-051736","article-title":"Precision (personalized) nutrition: Understanding metabolic heterogeneity","volume":"11","author":"SH Zeisel","year":"2020","journal-title":"Annu Rev Food Sci Technol"},{"issue":"6","key":"pmed.1005274.ref035","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"L Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"pmed.1005274.ref036","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1753-4887.2010.00287.x","article-title":"Fatty acids from fish: The anti-inflammatory potential of long-chain omega-3 fatty acids","volume":"68","author":"R Wall","year":"2010","journal-title":"Nutr Rev"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1005274","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:53:13Z","timestamp":1791913993000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005274"}},"subtitle":[],"editor":[{"given":"Isabelle","family":"Dehaene","sequence":"first","affiliation":[{"name":"University Hospital Ghent: Universitair Ziekenhuis Gent","place":["BELGIUM"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1005274","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}